338 related articles for article (PubMed ID: 19690035)
21. 18F-FDG PET/CT to Predict Response to Neoadjuvant Chemotherapy and Prognosis in Inflammatory Breast Cancer.
Champion L; Lerebours F; Alberini JL; Fourme E; Gontier E; Bertrand F; Wartski M
J Nucl Med; 2015 Sep; 56(9):1315-21. PubMed ID: 26159587
[TBL] [Abstract][Full Text] [Related]
22. Use of 18F-FDG-PET-CT for Assessment of Response to Neoadjuvant Chemotherapy in Children With Wilms Tumor.
Qin Z; Tang Y; Wang H; Cai W; Fu H; Li J; Ma C
J Pediatr Hematol Oncol; 2015 Jul; 37(5):396-401. PubMed ID: 25749587
[TBL] [Abstract][Full Text] [Related]
23. Induction chemotherapy in Barrett cancer: influence on surgical risk and outcome.
Siewert JR; Lordick F; Ott K; Stein HJ; Weber WA; Becker K; Peschel C; Fink U; Schwaiger M
Ann Surg; 2007 Oct; 246(4):624-8; discussion 628-31. PubMed ID: 17893499
[TBL] [Abstract][Full Text] [Related]
24. Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: implications from initial experience with 18F-FDG PET/CT.
Groves AM; Win T; Screaton NJ; Berovic M; Endozo R; Booth H; Kayani I; Menezes LJ; Dickson JC; Ell PJ
J Nucl Med; 2009 Apr; 50(4):538-45. PubMed ID: 19289428
[TBL] [Abstract][Full Text] [Related]
25. 11C-methionine vs. 18F-FDG PET in soft tissue sarcoma patients treated with neoadjuvant therapy: preliminary results.
Ghigi G; Micera R; Maffione AM; Castellucci P; Cammelli S; Ammendolia I; Nanni C; Barbieri E; Grassetto G; Fanti S; Rubello D
In Vivo; 2009; 23(1):105-10. PubMed ID: 19368133
[TBL] [Abstract][Full Text] [Related]
26. PET monitoring of therapy response in head and neck squamous cell carcinoma.
Schöder H; Fury M; Lee N; Kraus D
J Nucl Med; 2009 May; 50 Suppl 1():74S-88S. PubMed ID: 19380408
[TBL] [Abstract][Full Text] [Related]
27. Usefulness of increased 18F-FDG uptake for detecting local recurrence in patients with extremity osteosarcoma treated with surgical resection and endoprosthetic replacement.
Chang KJ; Kong CB; Cho WH; Jeon DG; Lee SY; Lim I; Lim SM
Skeletal Radiol; 2015 Apr; 44(4):529-37. PubMed ID: 25431093
[TBL] [Abstract][Full Text] [Related]
28. 18F-FDG positron emission tomography for the assessment of histological response to neoadjuvant chemotherapy in osteosarcomas: a meta-analysis.
Hongtao L; Hui Z; Bingshun W; Xiaojin W; Zhiyu W; Shuier Z; Aina H; Yuanjue S; Daliu M; Zan S; Yang Y
Surg Oncol; 2012 Dec; 21(4):e165-70. PubMed ID: 22884956
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET.
Schulte M; Brecht-Krauss D; Werner M; Hartwig E; Sarkar MR; Keppler P; Kotzerke J; Guhlmann A; Delling G; Reske SN
J Nucl Med; 1999 Oct; 40(10):1637-43. PubMed ID: 10520703
[TBL] [Abstract][Full Text] [Related]
30. 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience.
Ledezma CJ; Chen W; Sai V; Freitas B; Cloughesy T; Czernin J; Pope W
Eur J Radiol; 2009 Aug; 71(2):242-8. PubMed ID: 18511228
[TBL] [Abstract][Full Text] [Related]
31. Response of osteogenic sarcoma to neoadjuvant therapy: evaluated by 18F-FDG-PET.
Ye Z; Zhu J; Tian M; Zhang H; Zhan H; Zhao C; Yang D; Li W; Lin N
Ann Nucl Med; 2008 Jul; 22(6):475-80. PubMed ID: 18670853
[TBL] [Abstract][Full Text] [Related]
32. Comparison of 99mTc-methyl diphosphonate bone scintigraphy and 18F-fluorodeoxyglucose positron emission tomography/computed tomography to predict histologic response to neoadjuvant chemotherapy in patients with osteosarcoma.
Lee I; Byun BH; Lim I; Kim BI; Kong CB; Song WS; Cho WH; Koh JS; Lim SM
Medicine (Baltimore); 2018 Sep; 97(37):e12318. PubMed ID: 30212975
[TBL] [Abstract][Full Text] [Related]
33. SUV correction for injection errors in FDG-PET examination.
Miyashita K; Takahashi N; Oka T; Asakawa S; Lee J; Shizukuishi K; Inoue T
Ann Nucl Med; 2007 Dec; 21(10):607-13. PubMed ID: 18092139
[TBL] [Abstract][Full Text] [Related]
34. Intermodality comparison between 3D perfusion CT and 18F-FDG PET/CT imaging for predicting early tumor response in patients with liver metastasis after chemotherapy: preliminary results of a prospective study.
Kim DH; Kim SH; Im SA; Han SW; Goo JM; Willmann JK; Lee ES; Eo JS; Paeng JC; Han JK; Choi BI
Eur J Radiol; 2012 Nov; 81(11):3542-50. PubMed ID: 22459347
[TBL] [Abstract][Full Text] [Related]
35. Plasma proteome predicts chemotherapy response in osteosarcoma patients.
Li Y; Dang TA; Shen J; Hicks J; Chintagumpala M; Lau CC; Man TK
Oncol Rep; 2011 Feb; 25(2):303-14. PubMed ID: 21165584
[TBL] [Abstract][Full Text] [Related]
36. Comparison of two region of interest definition methods for metabolic response evaluation with [¹⁸F]FDG-PET.
Vriens D; De Geus-Oei LF; Van Laarhoven HW; Van Der Heijden HF; Krabbe PF; Visser EP; Oyen WJ
Q J Nucl Med Mol Imaging; 2010 Dec; 54(6):677-88. PubMed ID: 21221073
[TBL] [Abstract][Full Text] [Related]
37. TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study.
Wunder JS; Gokgoz N; Parkes R; Bull SB; Eskandarian S; Davis AM; Beauchamp CP; Conrad EU; Grimer RJ; Healey JH; Malkin D; Mangham DC; Rock MJ; Bell RS; Andrulis IL
J Clin Oncol; 2005 Mar; 23(7):1483-90. PubMed ID: 15735124
[TBL] [Abstract][Full Text] [Related]
38. Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters.
Denecke T; Hundsdörfer P; Misch D; Steffen IG; Schönberger S; Furth C; Plotkin M; Ruf J; Hautzel H; Stöver B; Kluge R; Bierbach U; Otto S; Beck JF; Franzius C; Henze G; Amthauer H
Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1842-53. PubMed ID: 20505933
[TBL] [Abstract][Full Text] [Related]
39. PET/CT for therapy response assessment in lymphoma.
Hutchings M; Barrington SF
J Nucl Med; 2009 May; 50 Suppl 1():21S-30S. PubMed ID: 19380407
[TBL] [Abstract][Full Text] [Related]
40. [Osteosarcoma: magnetic resonance imaging of the effects of preoperative chemotherapy].
Spina V; Torricelli P; Manfrini M; Picci P; Romagnoli R
Radiol Med; 1993 Jun; 85(6):725-32. PubMed ID: 8337428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
